Medigene AG (0QGJ.L)
- Globe Newswire
Medigene AG Reports Full-Year 2022 Financial Results and Provides Corporate Update
Continued progress in 2022 with corporate strategy update, end-to-end platform innovation, pipeline expansion, and acceleration of lead candidate developmentPartnering momentum continues with a $3 million milestone payment from 2seventy bioStrengthened leadership with key hires in Corporate Development & Strategy, Investor Relations & Corporate Communications and Clinical Research & DevelopmentCash runway maintained through 4Q 2024Company to host a conference call today, March 29, 2023, at 3 pm
- Globe Newswire
Medigene AG to present at the 4th TCR-based Therapies for Solid Tumors Summit in Boston
Martinsried/Munich, March 28, 2023. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an early-stage immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will be presenting at the 4th TCR-based Therapies for Solid Tumors Summit in Boston from April 3 to 5, 2023. On April 4, 2023, Prof. Schendel will first join the Industry Leaders’ Fireside Chat ”What’s Next for T-Cell Receptor Therapies?”, followed by her presentation (see detai
- Globe Newswire
Medigene AG Announces Appointment of Dr. Kirsty Crame, MD, as Head of Clinical Research & Development
Martinsried/Munich, March 20, 2023. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an early stage immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, announced today the appointment of Kirsty Crame, MD as Vice President, Head of Clinical Research & Development. “We are delighted to welcome Kirsty to Medigene to lead our clinical development activities. Her capabilities in drug development and proven track record of setting st
